Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Operating Expenses (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Operating Expenses for 5 consecutive years, with $6.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 50.45% to $6.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.9 million, a 65.1% decrease, with the full-year FY2024 number at $97.9 million, up 42.52% from a year prior.
  • Operating Expenses was $6.3 million for Q3 2025 at Lyra Therapeutics, down from $9.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $49.6 million in Q2 2024 to a low of $6.3 million in Q3 2025.
  • A 5-year average of $15.4 million and a median of $13.9 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 192.27% in 2024, then plummeted 81.83% in 2025.
  • Lyra Therapeutics' Operating Expenses stood at $13.9 million in 2021, then rose by 9.04% to $15.2 million in 2022, then increased by 9.61% to $16.6 million in 2023, then plummeted by 30.11% to $11.6 million in 2024, then tumbled by 46.1% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Operating Expenses are $6.3 million (Q3 2025), $9.0 million (Q2 2025), and $9.0 million (Q1 2025).